Apyx Medical Corp
Apyx Medical Corporation (NASDAQ: APYX) is a surgical aesthetics company focused on developing and commercializing innovative energy-based medical devices for cosmetic and surgical applications. The company operates through two reportable segments: Surgical Aesthetics, which contributed 85.8% of consolidated revenue… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Apyx Medical Corp does
In the company’s own words
Apyx Medical Corporation (NASDAQ: APYX) is a surgical aesthetics company focused on developing and commercializing innovative energy-based medical devices for cosmetic and surgical applications. The company operates through two reportable segments: Surgical Aesthetics, which contributed 85.8% of consolidated revenue in 2025, and OEM, which accounted for 14.2% of revenue.
The company's core product portfolio centers on its proprietary Helium Plasma Platform Technology, marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. These products enable surgeons to deliver controlled heat to tissue for cutting, coagulation, and ablation during open and minimally invasive procedures. In May 2025, Apyx received FDA clearance for AYON, an all-in-one body contouring system that integrates fat removal, closed-loop contouring, tissue contraction, and electrosurgical capabilities. The company also commercialized Renuvion in China following regulatory clearance in July 2025.
Apyx manufactures the majority of its products at facilities in Clearwater, Florida and Sofia, Bulgaria, both certified under ISO 13485:2016 standards. The company maintains a direct sales force in the United States and an international distributor network for product distribution. As of December 31, 2025, Apyx employed 205 full-time employees worldwide.
The company's intellectual property portfolio includes 41 issued U.S. patents and 61 foreign patents, with additional pending applications. Apyx has established 10 U.S. registered trademarks and 32 international registered trademarks.
The company operates in the cosmetic surgery market, which encompasses surgical, minimally invasive, and nonsurgical procedures. Apyx competes primarily against liposuction device manufacturers including Solta Medical and MicroAire Surgical Instruments. The company maintains a joint venture with a Chinese supplier in which it holds a 51% ownership interest, established to serve the Chinese market.
More information is available at www.apyxmedical.com.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- CLEARWATER, FL
- Fiscal year end
- December
- CIK
- 719135
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Apyx Medical Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Apyx Medical Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Apyx Medical Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Apyx Medical Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Apyx Medical Corp's last four quarterly filings that the numbers alone won't show?”